Page 16 - David Ricks News Today

Over 60% of CEOs surveyed by AlixPartners are worried their executive teams aren't agile enough to navigate today's fast pace of change.

Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December, and that its 2024 supply may not be enough to meet demand. "I think it's important to set expectations, but we're working hard to fulfill demand," he told Reuters at the annual JPMorgan health conference in San Francisco. Ricks declined to provide details on how much Zepbound Lilly can produce now, or to forecast 2024 d...

The maker of Zepbound and Mounjaro launched a new platform to connect patients and prescribers.

CNBC’s Jim Cramer told investors to pay attention next week to the JPMorgan Healthcare Conference.

CNBC's Jim Cramer told investors to pay attention next week to the JPMorgan Healthcare Conference.

Eli Lilly, which makes obesity and diabetes drugs like Zepbound and Mounjaro, has launched a new website that connects patients to telehealth services, but the service worries some health experts.

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound. The drugmaker said Thursday it will use the site, called LillyDirect, to pair visitors with third-party mail-order pharmacies for prescriptions and to care providers through a virtual medical weight-loss clinic. The site […]

Doctor about ozempic in 2020. she says he eventually prescribed it, but kept her on a low dose for a year, even though her weight wasnt changing. so she asked about a higher dose or other medications. you felt like you needed to keep raising the issue? >> thats it. i have seen physicians who almost seem afraid to be proactive with people who are overweight. and i think that really impedes getting access to good care. >> reporter: both ozempic and mounjaro are drugs for diabetes, but also used of...

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

The platform, called LillyDirect, joins a growing field of websites offering telehealth prescriptions for weight loss drugs.